Chimeric receptors targeting muc16 and uses thereof
AssigneesMemorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases
InventorsParwiz ABRAHIMI, Nan CHEN, Renier J. BRENTJENS, Jedd D. WOLCHOK, Taha MERGHOUB
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides for chimeric receptors that target MUC16 and cells comprising such chimeric receptors. The presently disclosed subject matter further provides uses of the chimeric receptors for treatment.
Claims30
A chimeric receptor, comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular domain comprises a mesothelin polypeptide that binds to MUC16 and comprises an amino acid sequence that is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO:
- 1 or a fragment thereof.
The chimeric receptor of any one of claims 1-11, wherein a signal peptide is covalently joined to the N-terminus of the extracellular domain.
Dependencies are inferred from the claim text.